Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages

European Respiratory Journal

Volumn 36, Issue 1, 2010, Pages 178-186

  Donnelly, L E ^a   Tudhope, S J ^a   Fenwick, P S ^a   Barnes, P J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Budesonide; Inflammation; Macrophage; Tumour necrosis factor

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BUDESONIDE; CYCLIC AMP; FORMOTEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; PROPRANOLOL; SALMETEROL; TUMOR NECROSIS FACTOR ALPHA; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CYTOKINE; ETHANOLAMINE DERIVATIVE; GLUCOCORTICOID; SALBUTAMOL;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; DRUG EFFECTS; LUNG ALVEOLUS MACROPHAGE; METABOLISM;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; BRONCHODILATOR AGENTS; BUDESONIDE; CYTOKINES; ETHANOLAMINES; GLUCOCORTICOIDS; HUMANS; MACROPHAGES, ALVEOLAR;

EID: 77954638595     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00158008     Document Type: Article

References (51)

1. Lohmann-Matthes ML, Steinmuller C, Franke-Ullmann G. Pulmonary macrophages. Eur Respir J 1994; 7: 1678-1689.
2. Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol 2004; 31: 3-7. (Pubitemid 38888032)
3. Tudhope SJ, Finney-Hayward TK, Nicholson AG, et al. Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J Pharmacol Exp Ther 2008; 324: 306-312.
4. Barnes PJ. Macrophages as orchestrators of COPD. COPD 2004; 1: 50-70.
5. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-a in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534.
6. Riise GC, Ahlstedt S, Larsson S, et al. Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax 1995; 50: 360-365.
7. Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15: 109-115. (Pubitemid 30068945)
8. Balbi B, Bason C, Balleari E, et al. Increased bronchoalveolar granulocytes and granulocyte/macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997; 10: 846-850. (Pubitemid 27180197)
9. Profita M, Chiappara G, Mirabella F, et al. Effect of cilomilast (Ariflo) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD. Thorax 2003; 58: 573-579.
10. Chung KF. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001; 18: Suppl. 34, 50s-59s.
11. Borish L, Mascali JJ, Dishuck J, et al. Detection of alveolar macrophage-derived IL-1b in asthma. Inhibitionwith corticosteroids. J Immunol 1992; 149: 3078-3082.
12. Linden M. The effects of β2-adrenoceptor agonists and a corticosteroid, budesonide on the secretion of inflammatory mediators from monocytes. Br J Pharmacol 1992; 107: 156-160.
13. Zetterlund A, Linden M, Larsson K. Effects of β2-agonists and budesonide on interleukin-1b and leukotriene B4 secretion: studies of human monocytes and alveolar macrophages. J Asthma 1998; 35: 565-573.
14. Hung CH, Chu YT, Hua YM, et al. Effects of formoterol and salmeterol on the production of Th1- and Th2-related chemokines by monocytes and bronchial epithelial cells. Eur Respir J 2008; 31: 1313-1321.
15. Baker AJ, Palmer J, Johnson M, et al. Inhibitory actions of salmeterol on human airway macrophages and blood monocytes. Eur J Pharmacol 1994; 264: 301-306. (Pubitemid 24335470)
16. Seldon PM, Barnes PJ, Meja K, et al. Suppression of lipopolysaccharide- induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995; 48: 747-757.
17. Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 2004; 66: 1679-1689.
18. Culpitt SV, Maziak W, Loukidis S, et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635-1639.
19. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD: Results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
20. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919. (Pubitemid 37540641)
21. Eickelberg O, Roth M, Lorx R, et al. Ligand-independent Activation of the Glucocorticoid Receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005-1010.
22. Oddera S, Silvestri M, Testi R, et al. Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation. Respiration 1998; 65: 199-204. (Pubitemid 28302299)
23. Silvestri M, Fregonese L, Sabatini F, et al. Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression. Eur Respir J 2001; 18: 139-145. (Pubitemid 32717441)
24. Korn SH, Jerre A, Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur Respir J 2001; 17: 1070-1077. (Pubitemid 32717460)
25. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006; 61: 250-258.
26. Winkler AR, Nocka KH, Sulahian TH, et al. In vitro modeling of human alveolar macrophage smoke exposure: enhanced inflammation and impaired function. Exp Lung Res 2008; 34: 599-629.
27. Traves SL, Smith SJ, Barnes PJ, et al. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 2004; 76: 441-450.
28. Schild HO. pAx and competitive drug antagonism. Br J Pharmacol Chemother 1949; 4: 277-280.
29. Clarke DL, Belvisi MG, Hardaker E, et al. E-ring 8-isoprostanes are agonists at EP2- and EP4-prostanoid receptors on human airway smooth muscle cells and regulate the release of colony-stimulating factors by activating cAMP-dependent protein kinase. Mol Pharmacol 2005; 67: 383-393.
30. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
31. Giembycz MA, Kaur M, Leigh R, et al. A Holy Grail of asthma management: toward understanding how long-acting β2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 2008; 153: 1090-1104.
32. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
33. Rabe KF, Giembycz MA, Dent G, et al. Salmeterol is a competitive antagonist at β-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol 1993; 231: 305-308.
34. Scola AM, Chong LK, Suvarna SK, et al. Desensitisation of mast cell β2-adrenoceptor-mediated responses by salmeterol and formoterol. Br J Pharmacol 2004; 141: 163-171.
35. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005; 128: 1936-1942.
36. Reid DW, Ward C, Wang N, et al. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J 2003; 21: 994-999.
37. Kaur M, Holden NS, Wilson SM, et al. Effect of β2- adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human airways smooth muscle cells: a role for protein kinase A. Am J Physiol Lung Cell Mol Physiol 2008; 295: L505-L514.
38. Baltathakis I, Alcantara O, Boldt DH. Expression of different NF-κB pathway genes in dendritic cells (DCs) or macrophages assessed by gene expression profiling. J Cell Biochem 2001; 83: 281-290. (Pubitemid 32896598)
39. Farmer P, Pugin J. β-Adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IκB/NF-κB pathway. Am J Physiol Lung Cell Mol Physiol 2000; 279: L675-L682.
40. Zhong H, SuYang H, Erdjument-Bromage H, et al. The transcriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997; 89: 413-424. (Pubitemid 27220886)
41. Scott MG, Swan C, Jobson TM, et al. Effects of a range of β2-adrenoceptor agonists on changes in intraceullar cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells. Br J Pharmacol 1999; 128: 721-729.
42. Munoz NM, Rabe KF, Vita AJ, et al. Paradoxical blockade of β-adrenergically mediated inhibition of stimulated eosinophil secretion by salmeterol. J Pharmacol Exp Ther 1995; 273: 850-854.
43. Magocsi M, Vizi ES, Selmeczy Z, et al. Multiple G-protein-coupling specificity of β-adrenoceptor in macrophages. Immunology 2007; 122: 503-513. (Pubitemid 350075946)
44. Ye RD. β-Adrenergic agonists regulate NF-κB activation through multiple mechanisms. Am J Physiol Lung Cell Mol Physiol 2000; 279: L615-L617.
45. Giembycz MA, Newton R. Beyond the dogma: novel β2- adrenoceptor signalling in the airways. Eur Respir J 2006; 27: 1286-1306.
46. Tanaka Y, Yamashita Y, Yamaki F, et al. Evidence for a significant role of a Gs-triggered mechanism unrelated to the activation of adenylyl cyclase in the cyclic AMP-independent relaxant response of guinea-pig tracheal smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 437-441.
47. Koike K, Yamashita Y, Horinouchi T, et al. cAMP-independent mechanism is significantly involved in β2-adrenoceptor mediated relaxation. Eur J Pharmacol 2004; 492: 65-70.
48. Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting β2-agonists. Curr Pharm Des 2006; 12: 3261-3279.
49. Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172: 704-712. (Pubitemid 41324225)
50. Korn SH, Wouters EFM, Wesseling G, et al. Interaction between glucocorticoids and β2-agonists: a and b glucocorticoid receptor mRNA expression in human bronchial epithelial cells. Biochemical Pharmacology 1998; 56: 1561-1569.
51. Kaur M, Chivers JE, Giembycz MA, et al. Long-acting β2- adrenoceptor agonists synergistically enhance glucocorticoiddependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 2008; 73: 203-214.